

# Xxxx Xxxx

xxx • xxxx • xxxx • [xxxxx@xxx.com](mailto:xxxxx@xxx.com)

## SUMMARY

---

### BIOPHARMACEUTICAL R&D EXECUTIVE

R&D leader with track record of innovation and development of meaningful products that address patients' unmet medical needs and yield multi-billion-dollars. Extensive experience in evaluation, selection, development, and commercialization of xxxxx across multiple therapeutic areas. Inspire and lead teams to sustainable, exceptional performance. Long-term, productive relationships within the FDA. Innovative, influential, and ethical.

- Built and/or transformed and led R&D organizations for three pharmaceutical companies.
- Led development that resulted in FDA approval for 10 new drugs and biologics and new indications for existing products.
- As Chair of the Xxxx Executive Committee, co-established the Xxxx - Xxx Partnership.
- Founder/Chair of xxxx, a nationwide drug development consortium to innovate and accelerate drug development, efficiencies, and outcomes.

## EXPERIENCE

---

**Xxxx** | Xxxxxx, PA. 2016 to Present.

**CHIEF SCIENCE OFFICER**—Led the R&D program and team in clinical stage projects, including xxxx, translational medicine and clinical programs. Oversee intellectual property development, project scope, budgeting, resource allocation, governance, and reporting.

- Built an efficient and effective translation and development organization that successfully executed a biomarker-driven program currently in Phase 2 and 3 trials.
- Transformed the Xxx program, advancing a technology without previous demonstrable efficacy for xxx beyond two weeks to a sustained, clinically effective product; paper published in *New England Journal of Medicine*.
- Cultivated relationships with major academic partners, including the Children's Hospital of Philadelphia and University of Pennsylvania.

**Xxxxx** | New York, NY. 2013 to 2016.

**PARTNER**—Identified, evaluated and invested in new biotechnology and medical device opportunities.

- Co-led licensing of Xxx and Xxxx; the latter was sold to Xxx for \$400M.

**Xxxxx** | Wilmington, DE. 2008 to 2013.

**CORPORATE VICE PRESIDENT – SCIENCE & TECHNOLOGY** (2012 to 2013)—Reviewed all major R& D programs and R&D-related acquisitions.

- Ex-Officio Member and Corporate Staff, Xxx Board of Directors Science & Technology Committee; Member, Board of Directors, Xxxx Development Corporation.

**GROUP PRESIDENT – XXXX R&D** (2010 to 2012)—Directed the Xxx global organization with 5,000+ staff and \$5B+ budget. Oversaw discovery, translation, development, and registration of new molecular entities. Effected a paradigm shift in R&D culture through addressing organization fragmentation, hiring new leadership, and motivating confidence and innovation.

- Chaired the Integrated Drug Development Committee, establishing stage gates and milestones facilitating 20+ successful late development programs with industry-leading benchmarks.
- Formalized and built Oncology Therapeutic Area leading to develop Xxxxs first targeted, approved cancer therapy, Xxxxx.

- Provided strategic leadership accelerating proof-of-concept and time to market; all programs exceeded industry benchmark times for therapeutic areas and resulted in approval for all products in US, EU and/or Japanese markets.
- Executed Xxxx program phase 1–3 submission within 30 months.
- Led acquisition of Xxxx as well as smaller acquisitions.
- Recipient, Discover’s Award, Xxxx Foundation for the Xxxx.
- Performance review: “The best drug developer of his generation.”

**SENIOR VICE PRESIDENT – DRUG DEVELOPMENT (2008 to 2010)**—Strategized and led the Xxxx development organization with 4,000+ global staff and \$4B budget. Optimized and restructured organizational design and recruited new leadership. Led licensing initiatives and chaired joint development committees. Built the pharmacokinetics modeling group and revamped governance processes.

- Reorganized the drug development organization from 8 consecutive phase 3 failures and lagging industry benchmarks to industry-leading success, world-class leaders, new therapeutic areas and product development teams, and novel stage gate and portfolio review processes.
- Chaired, Xxxx Integrated Drug Development Committee.
- Transformed Xxxx Pharmaceutical R&D by introducing comprehensive new processes for development stage gates, decision making, and advanced programs, improving development rate success by >90%.
- Led development of multi-billion-dollar innovations, including Xxxxxx, Xxxx, and Xxxxx.
- Reduced headcount by 25% and introduced efficiencies, saving approximately >\$1B annually, while improving productivity levels and enabling investment in new, lucrative programs and opportunities.

**Xxxxx** | Xxxxx, Xxx. 2005 to 2008.

**VICE PRESIDENT OF CLINICAL R&D**—Oversaw global clinical R&D development with 1,000 staff and a budget of \$500M+. Led Medical Affairs.

- Helped built an oncology franchise and led development of multiple products, including the first successful registration of Xxxx, which became a global \$2B product annually.

**Xxxxx** | Chesterbrook, PA. 1999 to 2005.

**VICE PRESIDENT – CLINICAL RESEARCH**—Served as clinical research physician overseeing Clinical Sciences, Medical Affairs, and US Drug Safety.

- Built Xxx’s clinical research organization from the ground up, recruited a world-class team of physicians, and led clinical development and/or new indications of Xxxxxx, Xxxxx, and Xxxx.
- Collaborated in driving sales of Xxx to \$4B+ and \$1B+ per year, respectively.
- Secured removal of box warning and approval of maintenance claim for Xxxx.
- Led first approvals of Xxx and xxx with peak sales > \$6 B and \$1B, respectively.
- Co-led clinical research mergers resulting in formation of Xxxx.

**Additional roles: Professor of Internal Medicine**, University of Xxxx School of Medicine; Adjunct Associate Professor, Department of Internal Medicine, Universit of Xxxx.

## EDUCATION

---

**Chief Resident in Medicine, Fellowship in Gastroenterology** | University of Xxxx Xxxx.

**M.D.** | University of Xxx. *Magna cum laude*

**B.S. in Biology** | University of Xxxx.

**ADDITIONAL INFORMATION**

---

**Fellowships**

American Institute of Medical and Biomedical Engineers • American College of Physicians • American College of Gastroenterology

**Certifications**

Board-Certified Internist & Gastroenterologist • Licensed Physician, Pennsylvania

**Representative Board of Directors Roles:**

Xxxx Foundation for the FDA; sole industry recipient of the Xxxx Award from FDA • Foundation for the NIH • Science Management Review Board of the NIH • Xxxx Medical School • Xxx Pharmaceuticals, Inc.

**Representative Chair Roles:**

Founder, Xxxx Biomedical, Inc. • Xxxx Foundation • Xxxx Science and Regulatory Executive Committee • Chair, Xxxxx Merit Review Board, Gastroenterology

**Representative Publications, Lectures & Patents**

Xxxxxx, *New England Journal of Medicine* xxx

Xxxx, *Aliment. Pharmacol. Ther.*, xxx

Xxxxx, *Am. J. Gastroenterol.*, xxx.

Xxxx, *Aliment. Pharmacol. Ther.* 10:1029-1033, 1996.

Xxxxx, Patent Xxxx, 2018.